BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), a
clinical-stage biotechnology company focused on patient-specific
immunotherapies for the treatment of cancer and infectious
diseases, today provided an update on its corporate progress and
reported financial results for the quarter and full year ended
December 31, 2019.
“2019 was transformational for BioNTech with
pipeline advancements, additional collaborations with leading life
science companies, and the completion of our initial public
offering,” said Ugur Sahin, BioNTech’s CEO. “We
have continued this strong momentum into 2020 against a challenging
market backdrop. We are continuing to advance our oncology pipeline
and, along with our partners Pfizer and Fosun Pharma, aim to dose
the first patient with our COVID-19 vaccine candidate within weeks.
We also continued our efforts to strengthen our cell therapy
capabilities and global footprint with our planned acquisition of
Neon Therapeutics in the U.S., and look forward to multiple new
trial starts and data read-outs across our pipeline during the
year.”
COVID-19 Vaccine Program
UpdateIn early March 2020 BioNTech announced details of
its efforts to develop a potential vaccine to induce immunity and
prevent COVID-19 infection. BioNTech is working to initiate
clinical testing for BNT162, a potential first-in-class mRNA
vaccine against COVID-19, in late April 2020.
As part of the program, BioNTech announced two
strategic collaborations with large pharma companies to ensure
global development of a vaccine candidate and global access to any
approved vaccine. BioNTech and Pfizer signed a letter of intent
regarding the co-development and distribution of a potential
mRNA-based coronavirus vaccine aimed at preventing COVID-19
infection. The collaboration aims to accelerate the
development of BNT162, building on the existing research and
development partnership between Pfizer and BioNTech signed in 2018,
under which the companies have been working together to develop
mRNA-based vaccines for prevention of influenza. The companies
expect to utilize multiple research and development sites from both
companies. Details of the agreement regarding financial terms and
all activities related to the development, manufacturing and
potential commercialization are expected to be finalized
shortly.
BioNTech also announced a strategic alliance
with Fosun Pharma to develop its COVID-19 vaccine in China. Under
the terms of the agreement, the two companies will work together on
the development of BNT162 in China, conducting clinical trials in
China and leveraging Fosun Pharma’s extensive clinical development,
regulatory, and commercial capabilities in the country. If
approved, Fosun Pharma will commercialize the vaccine in China.
Under the terms of the agreement, Fosun Pharma
agreed to make an equity investment of $50 million (€44
million) for 1,580,777 ordinary shares in BioNTech, subject to
execution of share subscription documentation and approval from
regulatory authorities in China.
Fourth Quarter 2019 and
Subsequent UpdatesIn addition to its
development efforts, as the global COVID-19 pandemic continues to
evolve, BioNTech has continuously monitored the situation in
regards to its operations and has put significant measures in place
to protect supply chain, operations, employees and the execution of
clinical trials. Given the dynamic global situation, BioNTech
notes there will be impacts to certain clinical trial timelines, as
noted below. BioNTech will continue to evaluate potential effects
and will provide updates as appropriate.
Oncology
FixVac
- BNT111 – Data from the ongoing Phase 1 trial in advanced
melanoma remains on track for publication in late 1H 2020. Based on
further regulatory discussions, the Company expects to initiate a
Phase 2 trial with registrational potential for BNT111 in 2H
2020.
- BNT112 – The first patient was dosed in a Phase 1/2a study in
patients with prostate cancer. Eligible patients for dose titration
have metastatic castration-resistant prostate cancer and will be
treated with BNT112 as a single agent. For the expansion phase,
patients with mCRPC and newly diagnosed high-risk, localized
prostate cancer (LPC) are eligible and will be treated with BNT112
alone or in combination.
- BNT114 – Data update from a Phase 1 trial in triple negative
breast cancer (TNBC) is now expected in 2H 2020. Data was
previously expected to be presented at The Association for Cancer
Immunotherapy (CIMT) Annual Meeting in May 2020. Given the
postponement of the conference, BioNTech is evaluating the
appropriate opportunity to present the data.
- BNT116 – The product candidate has been added to the FixVac
portfolio and is currently in preclinical development for non-small
cell lung cancer (NSCLC).
Individualized neoantigen specific immunotherapy
(iNeST)
- BNT121 – At the J.P. Morgan Health Care Conference in January
2020, BioNTech provided updated data from a Phase 1 trial for
BNT121, the precursor to RO7198457 (BNT122), our lead iNeST product
candidate. The data showed stable disease up to 60 months post
vaccination in a cohort of eight advanced melanoma patients who
were followed for relapse-free disease control following
vaccination with iNeST.
- BNT122 – BioNTech and Genentech disclosed that two additional
Phase 2 clinical trials in the adjuvant setting are planned for
initiation in 2020. The first adjuvant Phase 2 study will evaluate
the efficacy, safety, pharmacokinetics, immunogenicity and
biomarkers of RO7198457 plus atezolizumab compared with
atezolizumab alone in patients with Stage 2-3 non-small cell lung
cancer (NSCLC) who are circulating tumor DNA (ctDNA) positive
following surgical resection and have received standard-of-care
adjuvant platinum-doublet chemotherapy.
- BNT122 – Following changes to the timing of the American
Association for Cancer Research (AACR) Annual Meeting due to the
COVID-19 pandemic, we now expect the data update for the Phase 1/2
trial in multiple solid tumors to be presented in August 2020.
BioNTech expects to provide an enrollment update1 from the Phase 2
trial in first line melanoma in 2H 2020 with an interim data update
anticipated in 2021.
mRNA intratumoral immunotherapy
- BNT131 – Data update from Phase 1/2 trial in solid tumors
remains on track for 2H 2020.
Next-generation checkpoint immunomodulators
- BNT311 – BioNTech now expects to provide a data update from the
Phase 1/2 trial in multiple solid tumors (PD-L1x4-1BB) in 2H 2020,
ahead of our previous 1H 2021 expectations.
Targeted cancer antibodies
- BNT321 (MVT-5873) – Dosing has begun in the resumed Phase 1
study, evaluating the safety, maximum tolerated dose and
recommended Phase 2 dose of BNT321 as a single agent in patients
with pancreatic and other CA19-9 positive malignancies.
CAR-T cell immunotherapy
- BNT211 – Initiation of a Phase 1/2a trial in multiple solid
tumors (CLDN6) remains on track for 1H 2020.
- Publication in Science on the Company’s novel CAR-T therapeutic
approach for solid tumors which utilizes a CAR-T
Cell Amplifying RNA
Vaccine, or CARVac. The report entitled “An RNA
vaccine drives expansion and efficacy of claudin-CAR-T cells
against solid tumors” provides preclinical proof-of-concept data
for BioNTech’s first CAR-T product candidate BNT211.
Trial initiations for the following programs
have been delayed as a result of the COVID-19 pandemic.
Toll-Like Receptor Binding
- BNT411 – U.S. IND was approved in Q4 2019. A Phase 1/2a
clinical trial of BNT411 is now expected to be initiated as a mono-
or combination therapy in multiple solid tumors in 2H 2020.
Ribomabs
- BNT141 – Initiation of a Phase 1 trial in multiple solid tumors
is now expected in 1H 2021.
- BNT142 – Initiation of a Phase 1 trial in multiple solid tumors
(CD3+CLDN6) is now expected in 1H 2021.
RiboCytokines
- BNT151 – Initiation of a Phase 1 trial in multiple solid tumors
(optimized IL-2) is now expected in 1H 2021.
- BNT152+153 – Initiation of a Phase 1 trial in multiple solid
tumors is now expected in 1H 2021.
Rare Diseases
- BNT171 – Initiation of a Phase 1 trial in undisclosed
indication is now expected in 1H 2021.
Infectious Diseases
- BNT162 – Initiation of clinical testing for COVID-19 vaccine is
expected in April 2020.
- BNT161 – Initiation of clinical testing for a vaccine against
influenza is now expected in 1H 2021.
Corporate DevelopmentBioNTech
and Neon Therapeutics, Inc. (Nasdaq: NTGN) announced that they have
entered into a definitive merger agreement under which BioNTech
will acquire Neon in an all-stock transaction. Neon is a
biotechnology company developing novel neoantigen-based T cell
therapies and has deep expertise in the development of neoantigen
therapies, with both vaccine and T-cell capabilities. At closing,
BioNTech will issue, and Neon shareholders will receive, 0.063
American Depositary Shares (ADS) (each ADS representing one
ordinary share of BioNTech) in exchange for each of their shares of
Neon’s common stock. The transaction is expected to close during
the second quarter of 2020.
OperationsIn response to the
COVID-19 outbreak, we are continuing to assess our supply chain and
operations, which includes mRNA manufacturing for FixVac and iNeST
platform products, as well as our CAR-T manufacturing operations.
Our manufacturing operations are currently unaffected, but we will
continue to monitor the potential impact as the pandemic
develops.
In terms of our personnel, we have instituted a
range of precautionary measures to ensure their continued safety.
We are closely monitoring any employee that has potentially been in
any contact with affected individuals or in affected areas and
limiting access to BioNTech facilities as appropriate.
Full Year 2019 Financial
ResultsCash Position: Cash and cash equivalents as of
December 31, 2019, were €519.1 million.
Revenue: Total revenue, consisting primarily of
revenue from collaborative agreements, was €28.0 million for the
quarter ended December 31, 2019, compared to €63.8 million for the
quarter ended December 31, 2018. The decrease was primarily due to
decreased revenues from our collaboration with Sanofi. Total
revenue, consisting primarily of revenue from collaborative
agreements, was €108.6 million for the year ended December 31,
2019, compared to €127.6 million for the year ended December 31,
2018. The decrease was primarily due to decreased revenues from our
collaboration with Sanofi. The decrease in revenue from Sanofi is
primarily driven by a revenue of €33.2 million for a one-time
reimbursement of certain sublicense costs that was fully recognized
in the year ended December 31, 2018.
Research and Development Expenses: Research and
development expenses were €65.4 million for the quarter ended
December 31, 2019, compared to €51.8 million for the quarter ended
December 31, 2018. The increase was primarily due to an increase in
headcount and higher expenses incurred in our collaboration and own
clinical projects. Research and development expenses were €226.5
million for the year ended December 31, 2019, compared to €143.0
million for the year ended December 31, 2018. The increase was
primarily due to an increase in headcount, the full year impact of
our ESOP program and higher spending for purchased services and
laboratory supplies for our collaboration and own projects.
General and Administrative Expenses: General and
administrative expenses were €11.1 million for the quarter ended
December 31, 2019, compared to €10.1 million for the quarter ended
December 31, 2018. General and administrative expenses were €45.5
million for the year ended December 31, 2019, compared to €26.3
million for the year ended December 31, 2018. The increase was
primarily due to an increase in headcount and the full year impact
of our ESOP program.
Net Loss: Net loss was €58.2 million for the
quarter ended December 31, 2019, compared to net loss of €1.5
million for the quarter ended December 31, 2018. Net loss was
€179.2 million for the year ended December 31, 2019, compared to
net loss of €48.3 million for the year ended December 31, 2018.
Shares Outstanding: Shares outstanding as of
December 31, 2019 were 226,779,744.
Full financial statements can be found in the
20-F filing as published on the SEC website under
https://www.sec.gov/.
Conference Call and Webcast
InformationBioNTech SE will host a conference call and
webcast today at 08:00 a.m. ET (2:00 p.m. CET) to report its
financial results for the full year ended December 31, 2019 and
provide a corporate update.
The slide presentation and audio of the webcast
will be available via the following link:
https://edge.media-server.com/mmc/p/kxzxhy7k
To participate in the conference call, please
dial the following numbers 15-20 minutes prior to the start of the
call and provide the Conference ID: 1957628.
United States
international: |
+1 631 510
7495 |
United States domestic (toll-free): |
+1 866 966 1396 |
Germany: |
+49 692 443 7351 |
Participants may also access the slides and the
webcast of the conference call via the “Events & Presentations”
page of the Investor Relations section of the Company’s website at
https://biontech.de/. A replay of the webcast will be available
shortly after the conclusion of the call and archived on the
Company’s website for 30 days following the call.
About BioNTechBiopharmaceutical
New Technologies (BioNTech) is a next generation immunotherapy
company pioneering novel therapies for cancer and other serious
diseases. The Company exploits a wide array of computational
discovery and therapeutic drug platforms for the rapid development
of novel biopharmaceuticals. Its broad portfolio of oncology
product candidates includes individualized and off-the-shelf
mRNA-based therapies, innovative chimeric antigen receptor T cells,
bi-specific checkpoint immuno-modulators, targeted cancer
antibodies and small molecules. Based on its deep expertise in mRNA
vaccine development and in-house manufacturing capabilities,
BioNTech and its collaborators are developing multiple mRNA vaccine
candidates for a range infectious diseases alongside its diverse
oncology pipeline. BioNTech has established a broad set of
relationships with multiple global pharmaceutical collaborators,
including Eli Lilly and Company, Genmab, Sanofi, Bayer Animal
Health, Genentech, a member of the Roche Group, Genevant, Fosun
Pharma and Pfizer.
For more information, please visit:
www.BioNTech.de
Important Additional Information and
Where to Find ItIn connection with the proposed merger,
BioNTech will file with the Securities and Exchange Commission (the
“SEC”) a Registration Statement
on Form F-4 containing a proxy statement of
Neon and a prospectus of BioNTech, and each of Neon and BioNTech
may file with the SEC other documents regarding the proposed
merger. The definitive proxy statement will be mailed to
stockholders of Neon. INVESTORS AND SECURITY HOLDERS ARE URGED TO
READ THE REGISTRATION STATEMENT ON FORM F-4 AND THE PROXY
STATEMENT/PROSPECTUS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO
THOSE DOCUMENTS AND ANY OTHER RELEVANT DOCUMENTS TO BE FILED WITH
THE SEC IN CONNECTION WITH THE PROPOSED MERGER, WHEN THEY BECOME
AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT
BIONTECH, Neon AND THE PROPOSED MERGER.
Investors and security holders may obtain copies
of these documents free of charge through the website maintained by
the SEC at https://www.sec.gov or from BioNTech at its website,
https://biontech.de, or from Neon at its website, https://Neon.com.
Documents filed with the SEC by BioNTech will be available free of
charge by accessing BioNTech’s website under the heading
Investors & Media, or, alternatively, by directing a
request by telephone or mail to BioNTech at An der Goldgrube 12,
55131 Mainz, Germany, and documents filed with the SEC by Neon will
be available free of charge by accessing Neon’s website at
https://neontherapeutics.com under the heading Investor Resources
or, alternatively, by directing a request by telephone or mail to
Neon at 40 Erie Street, Suite 110, Cambridge, MA 02139,
USA.
No Offer or SolicitationThis
press release does not constitute an offer to sell or the
solicitation of an offer to buy any securities nor a solicitation
of any vote or approval with respect to the proposed transaction or
otherwise. No offering of securities shall be made except by means
of a prospectus meeting the requirements of Section 10 of the
U.S. Securities Act of 1933, as amended, and otherwise in
accordance with applicable law.
Participants in
SolicitationBioNTech and Neon and certain of their
respective directors and executive officers and other members of
management and employees may be deemed to be participants in the
solicitation of proxies from the stockholders of Neon in respect of
the proposed merger under the rules of the SEC. Information about
Neon’s directors and executive officers is available in Neon’s
definitive proxy statement dated April 26, 2019 for its 2019
Annual Meeting of Stockholders and certain of its Current Reports
on Form 8-K. Information about BioNTech’s directors and executive
officers is available in BioNTech’s Registration Statement on Form
F-1 filed with the SEC on September 9, 2019, as amended. Other
information regarding the participants in the proxy solicitation
and a description of their direct and indirect interests, by
security holdings or otherwise, will be contained in the proxy
statement/prospectus and other relevant materials to be filed with
the SEC regarding the proposed merger when they become available.
Investors should read the proxy statement/prospectus carefully when
it becomes available before making any voting or investment
decisions. You may obtain free copies of these documents from Neon
or BioNTech using the sources indicated above.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, as
amended including, but not limited to, statements concerning: the
planned next steps in BioNTech’s pipeline programs and specifically
including, but not limited to, statements regarding plans to
initiate clinical trials of BioNTech’s BNT111, iNeST (BNT122),
BNT141, BNT142, BNT151, BNT152/153, BNT211, and BNT411, and;
expectations for data announcements with respect to BioNTech’s
BNT111, BNT114, iNeST (BNT122), BNT131 and BNT311 clinical trials.
In some cases, forward-looking statements can be identified by
terminology such as “will,” “may,” “should,” “expects,” “intends,”
“plans,” “aims,” “anticipates,” “believes,” “estimates,”
“predicts,” “potential,” “continue,” or the negative of these terms
or other comparable terminology, although not all forward-looking
statements contain these words. The forward-looking statements in
this press release are neither promises nor guarantees, and you
should not place undue reliance on these forward-looking statements
because they involve known and unknown risks, uncertainties, and
other factors, many of which are beyond BioNTech’s control and
which could cause actual results to differ materially from those
expressed or implied by these forward-looking statements. You
should review the risks and uncertainties described under the
heading “Risk Factors” and those described in BioNTech’s Prospectus
filed with the U.S. Securities and Exchange Commission (SEC) on
September 9, 2019 and in subsequent filings made by BioNTech with
the SEC, which are available on the SEC’s website at
https://www.sec.gov/. Except as required by law, BioNTech disclaims
any intention or responsibility for updating or revising any
forward-looking statements contained in this press release in the
event of new information, future developments or otherwise. These
forward-looking statements are based on BioNTech’s current
expectations and speak only as of the date hereof.
______________________
1 We expect this data update to include an
update on the ongoing study, including patient enrollment numbers,
with full efficacy and safety data for an interim update expected
in the second half of 2021.
Consolidated Statements of Financial
Position
|
|
|
As of December 31, |
|
As of December 31, |
|
(in thousands) |
|
|
2019 |
|
2018 |
|
Assets |
|
|
|
|
Non-current assets |
|
|
|
|
Intangible assets |
|
|
€89,434 |
|
€88,042 |
|
Property, plant and equipment |
|
|
93,044 |
|
66,200 |
|
Right-of-use assets |
|
|
55,018 |
|
49,766 |
|
Other financial assets |
|
|
- |
|
18 |
|
Total non-current assets |
|
|
€237,496 |
|
€204,025 |
|
Current assets |
|
|
|
|
Inventories |
|
|
11,722 |
|
5,789 |
|
Trade receivables |
|
|
11,913 |
|
18,938 |
|
Other financial assets |
|
|
1,680 |
|
336 |
|
Other assets |
|
|
9,069 |
|
9,164 |
|
Income tax assets |
|
|
756 |
|
891 |
|
Deferred expense |
|
|
5,862 |
|
2,348 |
|
Cash and cash equivalents |
|
|
519,149 |
|
411,495 |
|
Total current assets |
|
|
€560,151 |
|
€448,961 |
|
Total
assets |
|
|
€797,647 |
|
€652,986 |
|
|
|
|
|
|
Equity and
liabilities |
|
|
|
|
Equity |
|
|
|
|
Share capital* |
|
|
232,304 |
|
193,296 |
|
Capital reserve* |
|
|
686,714 |
|
344,115 |
|
Treasury shares* |
|
|
(5,525 |
) |
- |
|
Accumulated losses |
|
|
(424,827 |
) |
(245,771 |
) |
Other reserves |
|
|
4,826 |
|
(25,487 |
) |
Equity
attributable to equity holders of the parent |
|
|
€493,492 |
|
€266,153 |
|
Non-controlling
interest |
|
|
- |
|
847 |
|
Total
equity |
|
|
€493,492 |
|
€267,000 |
|
Non-current liabilities |
|
|
|
|
Financial liabilities |
|
|
68,904 |
|
54,218 |
|
Contract
liabilities |
|
|
97,109 |
|
205,647 |
|
Total
non-current liabilities |
|
|
€166,013 |
|
€259,865 |
|
Current liabilities |
|
|
|
|
Tax provisions |
|
|
150 |
|
297 |
|
Provisions |
|
|
762 |
|
710 |
|
Financial liabilities |
|
|
1,823 |
|
- |
|
Trade payables |
|
|
20,498 |
|
41,721 |
|
Contract liabilities |
|
|
93,583 |
|
66,027 |
|
Other financial liabilities |
|
|
13,836 |
|
8,266 |
|
Other liabilities |
|
|
7,490 |
|
9,100 |
|
Total current
liabilities |
|
|
€138,142 |
|
€126,121 |
|
Total
liabilities |
|
|
€304,155 |
|
€385,986 |
|
Total equity
and liabilities |
|
|
€797,647 |
|
€652,986 |
|
* Numbers have been adjusted to reflect capital
increase due to 1:18 share split which occurred on September 18,
2019. |
Consolidated Statements of
Operations
|
|
|
Years endedDecember 31, |
|
|
|
2019 |
|
2018 |
|
2017 |
|
(in thousands, except
per share data) |
|
|
|
|
|
|
|
|
|
|
|
Revenues from contracts with customers |
|
|
€108,589 |
|
€127,575 |
|
€61,598 |
|
Cost of sales |
|
|
(17,361 |
) |
(13,690 |
) |
(9,318 |
) |
Gross
profit |
|
|
€91,228 |
|
€113,885 |
|
€52,280 |
|
|
|
|
|
|
|
Research and development expenses |
|
|
(226,466 |
) |
(143,040 |
) |
(85,496 |
) |
Sales and marketing expenses |
|
|
(2,718 |
) |
(3,041 |
) |
(6,603 |
) |
General and administrative expenses |
|
|
(45,547 |
) |
(26,334 |
) |
(23,520 |
) |
Other operating income |
|
|
2,724 |
|
5,396 |
|
2,349 |
|
Other operating
expenses |
|
|
(739 |
) |
(720 |
) |
(288 |
) |
Operating
loss |
|
|
€(181,518) |
|
€(53,854) |
|
€(61,277) |
|
|
|
|
|
|
|
Finance income |
|
|
4,122 |
|
8,046 |
|
2,133 |
|
Finance expenses |
|
|
(326 |
) |
(48 |
) |
(26,007 |
) |
Interest expense related to lease liability |
|
|
(1,718 |
) |
(1,721 |
) |
(676 |
) |
Share of loss of
equity method investees |
|
|
- |
|
(84 |
) |
(78 |
) |
Loss before
tax |
|
|
€(179,440) |
|
€(47,662) |
|
€(85,905) |
|
|
|
|
|
|
|
Income taxes |
|
|
268 |
|
(600 |
) |
(45 |
) |
Loss for the
period |
|
|
€(179,172) |
|
€(48,262) |
|
€(85,950) |
|
|
|
|
|
|
|
Attributable to: |
|
|
|
|
|
Equity holders of the parent |
|
|
(179,056 |
) |
(48,019 |
) |
(85,653 |
) |
Non-controlling
interests |
|
|
(116 |
) |
(243 |
) |
(297 |
) |
|
|
|
€(179,172) |
|
€(48,262) |
|
€(85,950) |
|
|
|
|
|
|
|
Earnings per share |
|
|
|
|
|
in EUR |
|
|
|
|
|
Basic & diluted, loss per share for the year attributable
to ordinary equity holders of the parent |
|
|
€(0.85) |
|
€(0.25) |
|
€(0.51) |
|
Consolidated Statements of Cash
Flows
|
|
Years endedDecember 31, |
|
|
2019 |
|
2018 |
|
2017 |
|
(in thousands) |
|
|
|
|
|
|
|
|
|
Operating activities |
|
|
|
|
Loss for the period |
|
€(179,172) |
|
€(48,262) |
|
€(85,950) |
|
Income taxes |
|
(268 |
) |
600 |
|
45 |
|
Loss before tax |
|
€(179,440) |
|
€(47,662) |
|
€(85,905) |
|
Adjustments to reconcile loss before tax to net cash
flows: |
|
|
|
|
Depreciation and amortization of property, plant, equipment and
intangible assets |
|
33,896 |
|
21,984 |
|
10,529 |
|
Share-based payment expense |
|
30,235 |
|
7,641 |
|
5,909 |
|
Net foreign exchange differences |
|
70 |
|
459 |
|
24,820 |
|
(Gain)/Loss on disposal of property, plant and equipment |
|
542 |
|
(14 |
) |
15 |
|
Finance income |
|
(1,782 |
) |
(1,996 |
) |
(2,133 |
) |
Interest on lease liability |
|
1,718 |
|
1,721 |
|
676 |
|
Finance expense |
|
326 |
|
48 |
|
53 |
|
Share of loss of an associate and a joint venture |
|
- |
|
84 |
|
78 |
|
Working capital adjustments: |
|
|
|
|
Decrease/(Increase) in trade receivable and contract assets |
|
2,939 |
|
(18,732 |
) |
(2,816 |
) |
Decrease/(Increase) in inventories |
|
(5,798 |
) |
(1,253 |
) |
(574 |
) |
(Decrease)/Increase in trade and other payables, contract
liabilities and provisions |
|
(80,577 |
) |
(21,080 |
) |
(4,574 |
) |
Interest received |
|
1,256 |
|
1,996 |
|
2,133 |
|
Interest paid |
|
(2,044 |
) |
(1,769 |
) |
(729 |
) |
Income tax received
(paid), net |
|
122 |
|
(304 |
) |
(45 |
) |
Net cash flows
used in operating activities |
|
€(198,537) |
|
€(58,877) |
|
€(52,562) |
|
|
|
|
|
|
Investing activities |
|
|
|
|
Purchase of property, plant and equipment |
|
(38,592 |
) |
(29,901 |
) |
(24,320 |
) |
Proceeds from sale of property, plant and equipment |
|
21 |
|
705 |
|
5,193 |
|
Purchase of intangibles assets |
|
(32,488 |
) |
(37,256 |
) |
(33,422 |
) |
Acquisition of subsidiaries and businesses, net of cash
acquired |
|
(6,056 |
) |
- |
|
- |
|
Net cash flows used in investing activities |
|
€(77,115) |
|
€(66,452) |
|
€(52,549) |
|
|
|
|
|
|
Financing activities |
|
|
|
|
Proceeds from issuance of share capital, net of costs |
|
375,351 |
|
361,725 |
|
- |
|
Proceeds from loans and borrowings |
|
11,000 |
|
5,600 |
|
- |
|
Payment of finance
lease liabilities |
|
(3,061 |
) |
(2,148 |
) |
(1,643 |
) |
Net cash flows
from/(used in) financing activities |
|
€383,290 |
|
€365,177 |
|
€(1,643) |
|
|
|
|
|
|
Net increase/(decrease) in cash and cash equivalents |
|
107,638 |
|
239,848 |
|
(106,753 |
) |
Change in cash resulting from exchange rate differences |
|
16 |
|
(459 |
) |
(24,820 |
) |
Cash and cash
equivalents at January 1 |
|
411,495 |
|
172,106 |
|
303,680 |
|
Cash and cash
equivalents at December 31 |
|
€519,149 |
|
€411,495 |
|
€172,106 |
|
Investor RelationsSylke Maas, Ph.D. VP Investor
Relations & Business Strategy Tel: +49 (0)6131 9084 1074
E-mail: Investors@biontech.de
Media RelationsJasmina AlatovicSenior Manager
Global External Communications Tel: +49 (0)6131 9084 1513 or +49
(0)151 1978 1385 E-mail: Media@biontech.de
Neon Therapeutics (NASDAQ:NTGN)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Neon Therapeutics (NASDAQ:NTGN)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024